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An immunohistochemical study was performed using tissue microarrays and specific antibodies against matrix metalloproteinases
(MMPs) 1, 2, 7, 9, 11, 13, 14, and their tisullar inhibitors (TIMPs) 1, 2, and 3. More than 2600 determinations on cancer specimens
from 131 patients with primary ductal invasive tumours of the breast (65 with and 66 without distant metastasis) and controls were
performed. Staining results were categorised using a score based on the intensity of the staining and a specific software program
calculated the percentage of immunostained cells automatically. We observed a broad variation of the total immunostaining scores
and the cell type expressing each protein. There were multiple and significant associations between the expression of the different
MMPs and TIMPs evaluated and some parameters indicative of tumour aggressiveness, such as large tumour size, advanced tumour
grade, high Nottinham prognostic index, negative oestrogen receptor status, peritumoural inflammation, desmoplastic reaction, and
infiltrating tumoural edge. Likewise, the detection of elevated immunohistochemical scores for MMP-9, 11, TIMP-1, and TIMP-2, was
significantly associated with a higher rate of distant metastases. The expression of MMP-9 or TIMP-2 by tumour cells, MMP-1, 7, 9, 11,
13, or TIMP-3 by fibroblastic cells, and MMP-7, 9, 11, 13, 14, TIMP-1, or TIMP-2 by mononuclear inflammatory cells, was also
significantly associated with a higher rate of distant metastases.
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Relapse in the form of metastases within 5 years of surgery
occurs in about half the women with primary breast cancer with
originally apparently localised tumours. However, it is difficult to
predict this event because breast cancer is a heterogeneous disease
encompassing a variety of pathological entities and a wide range
of clinical behaviours, even in patient groups that appear to
be clinically similar. Therefore, and despite having a number of
classical prognostic variables available, new prognostic factors
should be identified to improve the present risk classification and
thereby to develop a more rational management of breast cancer
patients.
Tumour invasion and metastasis development are the primary
determinants of patient outcome and, accordingly, molecules
involved in these processes are obvious candidates to be identified
as new prognostic markers in breast cancer. Degradation of the
stromal connective tissue and basement membrane components
are key elements in tumour invasion and metastasis. Proteolytic
enzymes of various classes execute the breaking down of matrix
elements. However, some components, particularly the interstitial
collagens, are very resistant to proteolytic attacks, being degraded
only by matrix metalloproteinases (MMPs) (Nelson et al, 2000).
The human MMP family currently consists of 28 members of
homologous zinc-dependent endopeptidases that can be divided
into eight structural classes or, on the basis of their substrate
specificity and primary structure, into the more familiar subgroups
of collagenases (MMP-1, 8, and 13), gelatinases (MMP-2 and 9),
stromelysins (MMP-3, 10, and 11), membrane-associated MMPs
(MMP-14, 15, 16, 17, 23, 24, and 25), and other novel MMPs
(Brinckerhoff et al, 2000; Overall and Lopez-Otin, 2002; Demers
et al, 2005). Matrix metalloproteinases are synthesised as inactive
zymogens, which are then activated predominantly pericellularly
either by other MMPs or by serine proteases. The activity of
MMPs is specifically inhibited by the so-called tissue inhibitors of
metalloproteases (tisullar inhibitors (TIMPs)). Currently, four
different TIMPs are known to exist: TIMPs 1, 2, 3, and 4.
There are available data clearly challenging the classic dogma
stating that MMPs promote metastases exclusively by modulating
the remodelling of extracellular matrix, as MMPs able to impact
in vivo on tumour cell behaviour as a consequence of their ability
to cleave growth factors, cell surface receptors, cell adhesion
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smolecules, or chemokines/cytoquines have also been identified
(Manes et al, 1999; Noe et al, 2001; Egeblad and Werb, 2002; Turk
et al, 2004). Furthermore, by cleaving proapoptotic factors, MMPs
are able to produce a more aggressive phenotype via generation
of apoptotic resistant cells (Fingleton et al, 2001). Matrix
metalloproteinases may also regulate cancer/related angiogenesis,
both positively through their ability to mobilise or activate
proangiogenic factors (Stetler-Stevenson, 1999) and negatively
via generation of angiogenesis inhibitors, such as angiostatin and
endostatin, cleaved from large protein precursors (Cornelius et al,
1998). In addition, it is now assumed that TIMPs are multifactorial
proteins also involved in the induction of proliferation and the
inhibition of apoptosis (Jiang et al, 2002; Wurtz et al, 2005).
The objectives of the present work were to evaluate the
morphological expression and clinical relevance of several MMPs
and TIMPs of biological importance in invasive ductal carcinomas
of the breast, by using the tissue microarray (TMA) technique,
which has allowed us to process a large number of tissue
specimens for a wide range of protein determinations (Kononen
et al, 1998; Camp et al, 2000).
MATERIALS AND METHODS
Patients’ selection, patients’ characteristics, and tissue
specimen handling
This study comprised 131 women with a histologically confirmed
diagnosis of early breast cancer and treated between 1990 and
2001. We selected women with the following inclusion criteria:
invasive ductal carcinoma, at least 10 histopathologicallyassessed
axillary lymph nodes, and a minimum of 5 years of follow-up in
those women without tumoral recurrence. The exclusion criteria
were the following: metastatic disease at presentation, prior history
of any type of malignant tumour, bilateral breast cancer at
presentation, having received any type of neoadjuvant therapy,
development of loco-regional recurrence during the follow-up
period, development of a second primary cancer, and absence
of sufficient tissue in the paraffin blocks used for manufacturing
the TMAs. From a total of 1053 patients fulfilling these criteria, we
selected randomly a sample size of 131 patients, in accordance with
four different groups of similar size and stratified with regard to
nodal status and with the development of metastatic disease, which
were the key measure variables of the study. Thus, we include an
important number of events in both node-negative and node-
negative patient subgroups (half the cases with distant metastasis
during the follow-up period in each one of these subgroups) for
securing the statistical power of the survival analysis. Patients’
characteristics included in the two main groups, with or without
distant metastases, are listed in Table 1. Nottingham prognostic
grade was assessed in accordance with Galea (1992).
Women were treated according to the guidelines used in our
institution. The study adhered to national regulations and was
approved by our institution’s Ethics and Investigation Committee.
The end point was distant metastatic relapse. The median follow-
up period in patients without metastasis was 87.5 months, and 52.7
months in patients with metastasis.
Tissue microarrays and immunohistochemistry
Routinely fixed (overnight in 10% buffered formalin), paraffin-
embedded tumour samples stored in our pathology laboratory files
were used in this study. Histopathologically representative tumour
areas were defined on haematoxylin and eosin (H&E)-stained
sections and marked on the slide. Tumour tissue array blocks were
obtained by punching a tissue cylinder (core) with a diameter of
1.5mm through a histologically representative area of each ‘donor’
tumour block, which was then inserted into an empty ‘recipient’
tissue array paraffin block using a manual tissue arrayer (Beecker
Instruments, Sun Praerie, Winconsin, USA) as described elsewhere
(Parker et al, 2002). Collection of tissue cores was carried out
under highly controlled conditions. Areas of non-necrotic
cancerous tissue were selected for arraying by two experienced
pathologists (LO Gonza ´lez and AM Merino). Two cores were
employed for each case. From the 131 tumour samples available,
four tissue array blocks were prepared, each containing 33 tumour
samples, as well as internal controls including four normal breast
tissue samples from two healthy women that underwent reductive
mammary surgery.
Four composite high-density TMA blocks were designed, and
serial 5mm sections were consecutively cut with a microtome
(Leica Microsystems GmbH, Wetzlar, Germany) and transferred to
Table 1 Basal characteristics of 131 patients with invasive ductal
carcinoma of the breast
Without recurrence With recurrence
Characteristics No. (%) No. (%)
Total cases 66 (100) 65 (100)
Age (years)
p58 32 (48.5) 38 (58.5)
458 34 (51.5) 27 (41.5)
Menopausal status
Premenopausal 21 (31.8) 18 (27.7)
Postmenopausal 45 (68.2) 47 (72.3)
Tumoural size
T1 36 (54.5) 27 (41.5)
T2 30 (45.5) 38 (58.5)
Nodal status
N(  ) 34 (51.5) 28 (43.1)
N (+) 32 (48.5) 37 (56.9)
Histological grade
a
Well Dif. 23 (34.8) 13 (20)
Mod. Dif. 29 (43.9) 35 (53.8)
Poorly Dif. 14 (21.2) 17 (26.1)
Nottingham pronostic index
o3.4 29 (63) 17 (37)
3.4–5.4 28 (46.7) 32 (53.3)
45.4 9 (36) 16 (64)
Estrogen receptors
a
Negative 26 (39.4) 36 (55.4)
Positive 40 (60.6) 29 (44.6)
Progesterone receptors
a
Negative 27 (37.9) 42 (64.6)
Positive 39 (59.1) 23 (35.4)
Adjuvant radiotherapy
No 48 (72.7) 33 (50.8)
Yes 18 (27.3) 32 (49.2)
Adjuvant systemic therapy
Chemotherapy 20 (30.3) 30 (46.2)
Adjuvant tamoxifen 26 (39.4) 15 (23.1)
Chemotherapy plus
sequential tamoxifen
11 (16.7) 7 (10.8)
No treatment 9 (13.6) 14 (21.5)
aCriteria reported by Bloom and Richardson. ER and PgR receptor measurements
were performed on cytosol extracts by using a enzyme immunoassay (Monoclonal
from Abbot Laboratories, Diagnostics Division, Wiesbaden, Germany). A value
higher than 10fmolmg
 1 total protein was considered as positive.
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sadhesive-coated slides. One section from each tissue array block
was stained with H&E, and these slides were then reviewed to
confirm that the sample was representative of the original tumour.
Immunohistochemistry was carried out on these sections of TMA
fixed in 10% buffered formalin and embedded in paraffin using
a TechMate TM50 autostainer (Dako, Glostrup, Denmark).
Antibodies for MMPs and TIMPs were obtained from Neomarker
(Lab Vision Corporation, Fremont, CA, USA). The dilution for
each antibody was established based on negative and positive
controls (1/50 for MMP-2, 7, and 14, TIMP-2 and 3; 1/100 for
MMP-1, 9, and 13 and TIMP-1; and 1/200 for MMP-11).
Tissue sections were deparaffinised in xylene, and then
rehydrated in graded concentrations of ethyl alcohol (100, 96, 80,
and 70%, then water). To enhance antigen retrieval only for
some antibodies, TMA sections were microwave-treated (H2800
Microwave Processor, EBSciences, East Granby, Connecticut,
USA) in citrate buffer (Target Retrieval Solution, Dako) at 991C
for 16min. Endogenous peroxidase activity was blocked
by incubating the slides in peroxidase-blocking solution (Dako)
for 5min. The EnVision Detection Kit (Dako) was used as
the staining detection system. Sections were counterstained
with haematoxilin, dehydrated with ethanol, and permanently
coverslipped.
TMA analysis
For each antibody preparation studied, the location of immuno-
reactivity, percentage of stained cells, and intensity were
determined. All the cases were semiquantified for each protein-
stained area. An image analysis system with the Olympus BX51
microscope and analysis soft (analySIS
s, Soft imaging system,
Mu ¨nster, Alemania) was employed as follows: tumour sections
were stained with antibodies according to the method explained
above and counterstained with haematoxilin. There are different
optical thresholds for both stains. Each core was scanned with a
 400 power objective in two fields per core. Fields were selected
searching for the protein-stained areas. The computer program
selects and traces a line around antibody-stained areas (higher
optical threshold: red spots), with the remaining, non-stained
areas (haematoxilin-stained tissue with lower optical threshold)
standing out as a blue background. Any field has an area ratio of
stained (red) vs non-stained areas (blue). A final area ratio was
obtained after averaging two fields. To evaluate immunostaining
intensity we used a numeric score ranging from 0 to 3, reflecting
the intensity as follows: 0, no staining; 1, weak staining; 2,
moderate staining; and 3, intense staining. Using an Excel
spreadsheet, the mean score was obtained by multiplying the
intensity score (I) by the percentage of stained cells (PC) and the
results were added together (total score: I PC). This overall score
was then averaged with the number of cores that were carried out
for each patient. If there was no tumour in a particular core, then
no score was given. In addition, for each tumour, the mean score
of two core biopsies was calculated.
Furthermore, whole-tissue sections from tumoural blocks from
a subset of 10 cases were compared with the corresponding TMA
discs, regarding each MMP and TIMP expression. Those cases
were selected randomly, and the obtained clinicopathological data
were very similar to those from the whole series. Each whole-tissue
section was scanned with a  400 power lens in 10 different fields.
Fields were selected searching for the protein-stained areas, as
described above.
Data analysis and statistical methods
Immunostaining score values for each protein were expressed as
median (range). Comparison of immunostaining values between
groups was made with the Mann–Whitney or Kruskall–Wallis
tests. Statistical results were corrected applying Bonferroni’s
correction. For metastasis-free survival analysis, we used Cox’s
univariate method. Cox’s regression model was used to examine
interactions of different prognostic factors in a multivariate
analysis. Expression profiles were analysed by the unsupervised
hierarchical clustering method that organises proteins in a tree
structure, on the basis of their similarity. Data were reformatted as
follows:  3 designated negative staining, 3 positive staining,
missing data was left blank. The score values were reformatted
(positive–negative) choosing the median as cutoff value. We used
the Cluster 3.0 program (average linkage, Pearson correlation).
Results were displayed with Treeview (Eisen et al, 1998). The SPSS
11.5 program was used for all calculations.
RESULTS
More than 2600 determinations in cancer specimens from 131
patients with primary invasive ductal carcinoma of the breast and
controls were performed on TMAs. Minimal internal variance of
score data between duplicate tissue cores from the same patients
was detected in the tissue arrays, showing a high agreement for
each protein (r40.95 and Po0.0001). In the validation study there
was total concordance in the global expression, as well as in the
intensity of immunostaining, for each MMP and TIMP between
TMA cases and the corresponding whole-tissue sections. In
addition, there were highly significant correlations in the
immunostaining scores between these two paired sets (r40.90
and Po0.0001, for each protein).
Figure 1 shows examples of TMAs with immunostaining for
each protein evaluated. There was a wide variability in the
immunostaining score values for each protein (Table 2). Immuno-
staining for all the proteins studied was localised predominantly
in tumour cells, but also in stromal cells in a significant percentage
of cases. There were significant associations between the total
immunostaining scores for several proteins and clinicopatho-
logical parameters of tumoral aggressiveness (Table 2).
We initially investigated the possible association between the
total immunostaining scores for each MMP and TIMP and the
relapse-free survival, taking the median value of the immunostain-
ing score for each protein as the cutoff point. Thus, we found that a
high expression of MMP-9 and 11, TIMP-1 and 2 was significantly
associated with a shortened relapse-free survival (Table 3 and
Figure 2). In addition, our data showed that the expression of
MMP-1, 7, 9, 11, 13, 14, TIMP-1, and 2, as a function of the cellular
type (tumour cell, fibroblast, and/or inflammatory mononuclear
cell) expressing the protein, was significantly associated with a
shorter relapse-free survival (Table 3 and Figure 2). Additionally,
to identify specific groups of tumours with distinct MMP/TIMP
immunohistochemical expression profiles, the data were analysed
by unsupervised hierarchical cluster analysis. The algorithm
orders proteins on the horizontal axis and samples on the vertical
axis based on similarity of their expression profiles. However, this
did not produce a dendrogram with a well-defined cluster of
tumours (Figure 3).
Multivariate analysis between classical prognostic factors
according to Cox model demonstrated that tumoral stage (II:
relative risk (RR) (confidence interval (CI))¼1.8(0.9–3.6); III:
3.9(2–8); Po0.001) and PgR status (positive: 0.36(0.2–0.6),
Po0.001) were significantly and independently associated with
relapse-free survival. All the MMP and TIMP expressions that
reached significance for predicting distant metastases in the
univariate analysis were significantly and independently associated
with relapse-free survival in the multivariate analysis (Table 3).
DISCUSSION
This is, to the best of our knowledge, the first study analysing the
expression of MMPs and TIMPs in human breast cancer by
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sapplying TMA technology, which allows one to integrate different
biological aspects of the tumour in the morphological context of
breast carcinoma.
Matrix metalloproteinases -2 (gelatinase A) and MMP-9
(gelatinase B) are related to tumour invasion and metastasis by
their special capacity to degrade the type IV collagen found in
basement membranes (Jones and Walker, 1997), and to induce
angiogenesis (Egeblad and Werb, 2002). Our results are in
accordance with those of previous reports showing that a high
MMP-9 expression correlates significantly with tumoral aggres-
siveness and poor prognosis (Chantrain et al, 2004; Li et al, 2004;
Pellikainen et al, 2004), as well as with other studies where high
MMP-2 expression in carcinoma cells, in contrast, has been related
to only a few inverse prognostic factors (Talvensaari-Mattila et al,
1998; Nakopoulou et al, 2003) or shown to have no association
with clinicopathological parameters in breast cancer (Jones et al,
1999; Hirvonen et al, 2003; Talvensaari-Mattila et al, 2003). It has
also been described that as breast cancer progresses, MMP-2
production increases during the early phases, whereas activation of
MMP-9 occurs during the late cancerous stage (Liotta and Kohn,
2001), which could explain their different impact on prognosis in
clinically detected invasive breast tumours.
Matrix metalloproteinase-1 (collagenase-1), the most ubiqui-
tously expressed of the interstitial collagenases, is required for
local invasion because it possesses the ability to efficiently degrade
type I collagen – the principal component of connective tissue
(Brinckerhoff et al, 2000). We found that high expression of MMP-
1 by fibroblast cells correlated with the occurrence of metastasis,
which is in accordance with previous studies showing that this
MMP is associated with elevated metastasis capacity (Kang et al,
2003; Prybylowska et al, 2006). Matrix metalloproteinase -7
(matrilysin 1) is a stromelysin, that degrades type IV collagen,
fibronectin and laminin. It was shown that MMP-7 is aberrantly
expressed in human breast tumours and that elimination of MMP-
7 is associated with low invasiveness and slow tumour growth (Jian
et al, 2005). Likewise, it has been recently reported that MMP-7
overexpression in breast cancer (MCF-7) cells enhances cellular
invasiveness and activation of proMMP-2 and MMP-9 (Wang et al,
2006). However, the potential role of MMP-7 in human breast
cancer, and particularly in clinical breast cancer, has not been
thoroughly investigated. Our results are in accordance with these
experimental studies showing that high intratumoral levels of
MMP-7 were significantly associated with several parameters
indicatives de tumoral aggressiveness and linked with a high
occurrence of distant metastasis.
Similarly to other studies, our data show that MMP-11
(Stromalysin-3) was preferentially expressed by peritumoral
stromal cells (Basset et al, 1990; Basset et al, 1997) and that high
levels of MMP-11 were associated with tumour progression and
poor prognosis (Chenard et al, 1996; Ahmad et al, 1998). Matrix
metalloproteinase -13 (collagenase-3) has been found to have an
exceptionally wide substrate specificity when compared with other
MMPs (Freije et al, 1994; Knauper et al, 1997). Moreover, it is
thought to play a central role in the MMP activation cascade, both
activating and being activated by several other MMPs (MMP-14, 2,
or 3). Nielsen et al (2001) have reported that MMP-13 expression
by myofibroblasts was often associated with microinvasive events,
and they have proposed that this MMP may play an essential
role during the transition of ductal carcinoma in situ lesions to
invasive ductal carcinoma of the breast. In the present study,
we found high MMP-13 expression in early-stage tumours, but
also associated with tumours showing an infiltrating edge and with
a higher rate of distant metastases when the MMP was expressed
by fibroblastic cells or by inflammatory mononuclear cells.
Matrix metalloproteinase -14 (membrane type 1 MMP, or MT1-
MMP) is a key metalloprotease involved in the degradation of
extracellular matrix, activates pro-MMP-13 (Knauper et al, 1996)
and pro-MMP-2 (Strongin et al, 1995) on the cell surface, and plays
crucial roles in molecular carcinogenesis, tumour cell growth,
invasion, and angiogenesis. In the present study, we found
significant associations between the expression of MMP-14 and
clinicopathological parameters indicative of tumour aggressive-
ness. The strong association between MMP-14 expression by
stromal cells and poor prognosis described in the present study is
also remarkable .
Our results showing a significant association between TIMP-1,
TIMP-2 and several parameters indicative of tumoral aggressive-
ness as well as with a high occurrence of distant metastases are in
accordance with similar findings reported by other authors (Ree
et al, 1997; Remacle et al, 2000; Schrohl et al, 2004). If TIMPs
inhibit MMPs in vivo, it should be expected that high levels of
these inhibitors would prevent tumour progression and thus be
MMP14
TIMP2 TIMP3
MMP2 MMP7 MMP9 MMP1
MMP11 MMP13 TIMP1
AB
CD
Figure 1 Left: examples of TMAs with immunostaining for each protein. 200  Right: (A) immunohistochemical staining of MMP2 in epithelial cells, (B)
TIMP3 in epithelial cells and fibroblastic cells, (C) TIMP3 in inflammatory mononuclear cells, and (D) TIMP2 in epithelial cells, fibroblast and inflammatory
mononuclear cells. 400 .
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TIMPs are multifunctional proteins that in addition to their MMP-
inhibitory effect also demonstrate distinct tumour-stimulatory
functions (Jiang et al, 2002).
Experimental studies have shown that TIMP-3 may show
activity to inhibit angiogenesis and induce apoptosis (Ahonen
et al, 1998; Spurbeck et al, 2002). It has also been published that
high TIMP-3 mRNA levels are associated with a good prognosis in
breast cancer (Kotzsch et al, 2005). Likewise, Span et al (2004)
have reported that high levels of TIMP-3 predicted a longer
relapse-free survival in patients treated with tamoxifen. All these
findings suggest that TIMP-3 is involved in specific pathways of
tamoxifen-induced apoptosis. Our results show a significantly
higher TIMP-3 expression in ER-positive tumors, in accordance
Table 2 Relationship between MMPs and TIMPs immunostaining score values and clinico-pathological characteristics in 131 patients with invasive ductal
carcinoma of the breast
Characteristics No. MMP-1 MMP-2 MMP-7 MMP-9 MMP-11 MMP-13 MMP-14 TIMP-1 TIMP-2 TIMP-3
Total cases 131 134 (0–285) 0 (246) 124 (0–270) 72 (0–273) 148 (0–279) 61 (0–234)107 (0–261) 144 (0–285) 115 (0–243) 110 (0–272)
Age (years)
p58 70 140 (20–285) 0 (0–207) 119 (0–270) 0 (0–264) 165 (0–279) 63 (0–180) 84 (0–261) 146 (0–285) 108 (0–243) 126 (0–272)
458 61 140 (35–285) 0 (0–246) 145 (0–267) 72 (0–273) 147 (0–276.8)59 (0–234) 81 (0–184.9)136 (0–273) 118 (0–243) 75 (0–264)
Menopausal status
Premenopausal 39 129 (20–285)23 (0–207) 102 (0–270) 69 (0–176) 157 (0–277) 63 (0–180) 81 (0–261) 134 (0–285) 78 (0–231) 135 (0–261)
Postmenopausal 92 140 (27–285) 0 (0–246) 132 (0–267) 73 (0–273) 156 (0–279) 60 (0–234) 85 (0–258) 149 (0–282) 120 (0–243) 110 (0–272)
Tumoral size Po0.05
T1 63 131 (20–285) 0 (0–198) 119 (0–258) 65 (0–273) 144 (0–279) 66 (0–192) 81 (0–231) 134 (0–276) 78 (0–243) 116 (0–272)
T2 68 142 (27–285) 0 (0–246) 131 (0–270) 79 (0–264) 163 (0–277) 58 (0–234) 86 (0–261) 150 (0–285) 123 (0–243) 103 (0–271)
Nodal status Po0.001 Po0.005
N(  ) 62 145 (20–285) 0 (0–207) 62 (0–243) 75 (0–273) 166 (0–279) 67 (0–234) 82 (0–261) 140 (0–276) 140 (0–243) 117 (0–272)
N (+) 69 140 (27–285) 0 (0–246) 151 (33–270)70(0–237) 152 (0–276) 56 (0–192) 84 (0–258) 144 (0–285) 108 (0–243) 96 (0–265)
Stage Po0.001 Po0.05
I 39 139 (20–285) 0 (0–136) 62 (0–160) 69 (0–273) 152 (0–279) 67 (0–147) 81 (0–231) 134 (0–276) 77 (0–243) 118 (0–272)
II 61 140 (35–285) 0 (0–207) 132 (0–270) 76 (0–264) 161 (0–277) 62 (0–234) 85 (0–261) 148 (0–285) 118 (0–243) 117 (0–271)
III 31 132 (27–285) 0 (0–246) 157 (33–262) 68 (0–237) 147 (0–273) 54 (0–192) 81 (0–258) 146 (0–282) 120 (0–243) 72 (0–260.4)
Histological grade Po0.05
Well Dif. 36 140 (35–277) 0 (0–246) 70 (0–247) 67 (0–264) 103 (0–263) 66 (0–234) 78 (0–184) 144 (0–270) 79 (0–243) 117 (0–261)
Mod. Dif. 64 138 (20–285) 0 (0–207) 145 (0–258) 74 (0–273) 161 (0–279) 61 (0–192) 82 (0–261) 134 (0–276) 124 (0–243) 94 (0–271)
Poorly Dif. 31 145 (27–285) 0 (0–134) 120 (0–270) 96 (0–180) 172 (0–273) 57 (0–136)121 (0–258) 151 (0–285) 74 (0–243) 94 (0–272)
Nottingham pronostic index Po0.005
o3.4 45 142 (20–285) 0 (0–136) 65 (0–239) 69 (0–273) 151 (0–279) 67 (0–234) 83 (0–261) 138 (0–276) 79 (0–243) 117 (0–261)
3.4–5.4 60 138 (33–285) 0 (0–246) 135 (0–267) 74 (0–237) 158 (0–277) 61 (0–192) 81 (0–255) 138 (0–276) 128 (0–243) 122 (0–272)
45.4 25 140 (27–285)47 (0–136) 139 (33–270) 82 (0–154) 159 (0–273) 56 (0–133)147 (0–258) 146 (0–285) 85 (0–180) 71 (0–264)
Oestrogen receptors Po0.01
Negative 62 136 (27–285)19 (0–246) 130 (0–267) 73 (0–273) 152 (0–279) 58 (0–147) 85 (0–258) 134 (0–282) 120 (0–243) 72 (0–263)
Positive 69 140 (20–285) 0 (0–207) 120 (0–270) 72 (0–237) 160 (0–277) 63 (0–234) 81 (0–261) 146 (0–285) 90 (0–243) 137 (0–272)
Progesterone receptors
Negative 69 135 (27–285) 0 (0–246) 129 (0–267) 75 (0–273)155.4 (0–277) 56 (0–147) 85 (0–258) 146 (0–282) 122 (0–243) 91 (0–271)
Positive 62 140 (20–285) 0 (0–207) 126 (0–270) 70 (0–237) 160 (0–279) 63 (0–234) 81 (0–261) 136 (0–285) 72 (0–243) 118 (0–272)
Desmoplastic reaction Po0.05 Po0.01
No 45 130 (20–285) 0 (0–207) 129 (0–267) 66 (0–273) 112 (0–277) 52 (0–180) 81 (0–261) 119 (0–273) 78 (0–243) 95 (0–272)
Yes 86 140 (27–285) 0 (0–246) 127 (0–270) 75 (0–264) 164 (0–279) 62 (0–234) 84 (0–258) 151 (0–285) 125 (0–243) 116 (0–262)
Peritumoral inflammation Po0.01 Po0.001
No 82 140 (20–285) 0 (0–136) 120 (0–267) 69 (0–180) 152 (0–279) 61 (0–234) 79 (0–231) 137 (0–282) 112 (0–243) 121 (0–272)
Yes 49 134 (35–285)47 (0–246) 130 (0–270) 75 (0–273) 161 (0–276.8)60 (0–192)154 (0–261) 150 (0–285) 118 (0–243) 74 (0–261)
Tumoral advancing edge Po0.05
Expansive 56 143 (20–285) 0 (0–136) 129 (0–262) 71 (0–264) 144 (0–279) 57 (0–180) 84 (0–261) 135 (0–276) 80 (0–243) 138 (0–272)
Infiltrating 75 140 (27–285) 0 (0–246) 125 (0–270) 75 (0–273) 164 (0–277) 63 (0–234) 82 (0–184) 150 (0–285) 124 (0–243) 81 (0–257)
Vascular invasion
No 85 140 (20–285) 0 (0–207) 119 (0–267) 71 (0–273) 148 (0–279) 60 (0–192) 82 (0–255) 136 (0–282) 118 (0–243) 116 (0–272)
Yes 46 136 (40–285) 0 (0–246) 142 (0–270) 74 (0–174) 164 (0–265) 63 (0–234) 84 (0–261) 149 (0–285) 111 (0–243) 100 (0–264)
Data are expressed as median (range). Statistical results were corrected applying Bonferroni’s correction. Samples on tissue sections were either insufficient or lost for analysis in
three cases for MMP1, two cases for MMP-2, four cases for MMP-7, one for MMP-9, two for MMP-11, one for TIMP-1 and one for TIMP-2. The values shown correspond to the
total of cases analyzed for each protein.
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swith a prior study (Span et al, 2004). However, we also found that
TIMP-3 expression by fibroblastic cells, but not by tumoural cells,
correlates positively with the occurrence of distant metastases,
reflecting the existence of other mechanisms in the molecular
biology of the breast tumours in which this TIMP might be
implicated.
In the present study, relevant our finding that the expression of
MMP-1, 7, 11, 14, TIMP-1, 2 or 3 by fibroblasts and/or by
inflammatory mononuclear cells was significantly associated with
a higher incidence of distant metastases was especially , suggesting
that the tumoral stroma does not play a merely passive role in
cancer progression. In fact, over the past few years evidence has
accumulated that both changes in stromal behaviour and the
interaction between tumour cells and stromal cells are intimately
linked to the processes of tumorgenesis, tumour invasion, and
metastasis (Liotta and Kohn, 2001; Klausner, 2002; Wiseman and
Werb, 2002). It has been demonstrated that several types of
malignant cells (eg, breast and colon) actively recruit fibroblasts
into tumours, leading to an increase in the extent of extracellular
matrix degradation (Sloane et al, 2005). Likewise, it has been
shown that incubation of breast cancer cells with monocytes or
macrophages induces a crosstalk that results in an increased
expression of factors involved in cancer cell invasiveness and in a
modification of the monocytes function against cancer cells (Blot
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Figure 2 Kaplan–Meier survival curves as function a of the immunostaining score values of MMP-9 (A), MMP-11 (B), TIMP-1 (C), and TIMP-2 (D);
expression by tumoral cells of MMP-9 (E) and TIMP-2 (F); expression by fibroblast cells of MMP-1 (G), MMP-7 (H), MMP-9 (I), MMP-11 (J), MMP-13 (K),
TIMP-2 (L), and TIMP-3 (M); expression by mononuclear inflammatory cells of MMP-7 (N), MMP-9 (O), MMP-11 (P), MMP-13 (Q), MMP-14 (R), TIMP-1
(S), and TIMP-2 (T).
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set al, 2003; Pukrop et al, 2006). We could hypothesise that tumours
secrete factors able to elicit a wound-repair response from tumour-
associated and tumour-infiltrating inflammatory cells, this
response inadvertently stimulating tumour progression (Queen
et al, 2005); or that it is the host tissue, with a redundant response
of biochemical factors to cancerous cells, that induces the tumour
growth. Even so, our data indicate a biological variability in the
behaviour of these stromal cells with regard to the expression of
MMPs and TIMPs, which is of clinical importance.
Our data also show that the expression of some MMPs and
TIMPs has a potential value as predictor of distant metastases
except for MMP-7 and MMP-14, without lymph node involvement.
By contrast, we have surprisingly found that the global expression
of TIMP-2 and MMP-13 correlated negatively with lymph node
Table 3 Cox’s univariate (HR) and multivariate (RR) analysis of the relationship between MMPs and TIMPs expression and relapse-free survival
Factor No. of patients Event frequency HR (95% CI) RR (95% CI)
MMP-1
Score omedian vs 4median 66/62 29/36 1.6 (0.9–2.6) —
Tumoural cells ( ) vs (+) 15/113 4/61 2.5 (0.9–6.9) —
Fibroblasts ( ) vs (+) 27/101 9/56 2.1 (1–4.3)**** —
MIC ( ) vs (+) 43/85 18/47 1.6 (0.9–2.9) —
MMP-2
Score omedian vs 4median 76/53 38/27 1 (0.6–1.7) —
Tumoral cells ( ) vs (+) 86/43 41/24 1.2 (0.7–2.1) —
Fibroblasts ( ) vs (+) 98/31 47/18 1.3 (0.7–2.3) —
MIC ( ) vs (+) 127/2 69/1 0.8 (0.1–6.1) —
MMP-7
Score omedian vs 4median 66/61 37/28 0.8 (0.5–1.4) —
Tumoural cells ( ) vs (+) 16/111 Jun-59 1.6 (0.7–3.7) —
Fibroblasts ( ) vs (+) 37/90 15/50 1.8 (1–3.2)*** 1.8 (1–3.2)****
MIC ( ) vs (+) 64/63 27/38 1.6 (1–2.7)*** —
MMP-9
Score omedian vs 4median 65/65 20/44 2.7 (1.6–4.7)* 2.6 (1.5–4.5)*
Tumoural cells ( ) vs (+) 35/95 7/57 3.7 (1.7–8.2)* 3.3 (1.5–7.4)**
Fibroblasts ( ) vs (+) 110/20 44/20 3.7 (2.2–6.4)* 3.1 (1.8–5.3)*
MIC ( ) vs (+) 116/19 50/14 3.6 (2–6.8)* 3 (1.6–5.5)*
MMP-11
Score omedian vs 4median 66/63 24/40 2.1 (1.3–3.6)** 2.5 (1.5–4.3)*
Tumoural cells ( ) vs (+) 15/114 4/60 2.1 (0.7–6.0) —
Fibroblasts ( ) vs (+) 41/88 7/57 5.7 (2.6–12.7)* 4.5 (2–10.1)*
MIC ( ) vs (+) 89/40 25/39 6.0 (3.5–10.1)* 4.5 (2.6–7.7)*
MMP-13
Score omedian vs 4median 66/65 35/30 0.7 (0.4–1.1) —
Tumoural cells ( ) vs (+) 34/97 17/48 0.8 (0.5–1.5) —
Fibroblasts ( ) vs (+) 67/64 24/41 2.0 (1.2–3.4)*** 1.9 (1.1–3.2)***
MIC ( ) vs (+) 87/44 35/30 2.1 (1.3–3.5)** 2.2 (1.3–3.7)**
MMP-14
Score omedian vs 4median 66/65 28/37 1.4 (0.9–2.4) —
Tumoural cells ( ) vs (+) 13/118 5/60 1.4 (0.5–3.3) —
Fibroblasts ( ) vs (+) 25/106 11/54 1.1 (0.6–2.2) —
MIC ( ) vs (+) 64/67 16/49 4.8 (2.7–8.8)* 4.4 (2.4–8.1)*
TIMP-1
Score omedian vs 4median 65/65 26/38 2.0 (1.2–3.3)** 1.7 (1.02–2.8)****
Tumoural cells ( ) vs (+) 8/123 3/62 1.8 (0.5–5.8) —
Fibroblasts ( ) vs (+) 67/64 36/29 0.8 (0.4–5.8) —
MIC ( ) vs (+) 98/33 37/28 2.8 (1.7–4.6)* 2.2 (1.3–3.7)*
TIMP-2
Score omedian vs 4median 65/65 17/47 3.7 (2.1–6.5)* 3.1 (1.7–5.5)*
Tumoural cells ( ) vs (+) 21/110 3/62 4.8 (1.5–15.4)*** 3.6 (1.1–11)****
Fibroblasts ( ) vs (+) 76/55 18/47 7.1 (4.0–12.5)* 5.7 (3.2–10.1)*
MIC ( ) vs (+) 81/50 25/40 3.4 (2.1–5.7)* 3.4 (2–5.7)*
TIMP-3
Score omedian vs 4median 66/65 31/39 0.9 (0.6–6.5) —
Tumoural cells ( ) vs (+) 18/113 9/56 1 (0.5–2) —
Fibroblasts ( ) vs (+) 51/80 16/49 2.4 (1.4–4.3)** 2 (1.1–3.7)***
MIC ( ) vs (+) 62/69 28/37 1.3 (0.7–2) —
Abbreviations: CI¼confidence interval; HR¼ hazard ratio; MIC¼mononuclear inflammatory cells; RR¼ relative risk. *Po0.001; **Po0.005; ***Po0.01; ****Po0.05.
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sinvolvement. Altogether, our data support the concept that the
biological mechanisms involved in blood vessel and lymphatic
dissemination are dependent on different processes within tumoral
pathophysiology. Nevertheless, we also have to consider that in the
present study, we investigated the intratumoral stroma, and the
putative absence of intratumoral lymphatics in invasive breast
carcinomas is well known (Vleugel et al, 2004). On the other hand,
it is also of note that we did not find well-defined cluster groups
with regard to scores of immunostaining values of MMPs and
TIMPs, which iis probably due to the biological heterogeneity of
breast cancer.
In summary, our results demonstrate the importance of MMPs
and TIMPs in the progression of breast cancer, and suggest their
value in order to reach a more precise prognostic estimation in
invasive ductal carcinoma of the breast.
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Figure 3 Graphical representation of two-dimensional unsupervised
hierarchical clustering results on immunohistochemistry expression profiles
of 10 proteins in 131 breast cancer samples. Rows: samples; columns,
proteins. Protein expression scores are depicted according to a colour
scale: red, positive staining; green, neative staining; grey, missing data.
Dendogram of samples (to the left of matrix) and proteins (above matrix)
represent overall similarities in expression profiles. Status column:1¼with
recurrence; 0, without recurrence, at the census point.
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